Physician profile
Alexander Holbrook
NPI 1003657594
$1,881.42
in general payments reported to CMS, 2019-2025
15 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $878 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,881.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $426.10 | 2024-2025 | Otezla, Repatha, Repatha |
| Organon LLC | $222.04 | 2024 | |
| Abbvie INC. | $213.18 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $208.61 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $121.82 | 2025 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.85 | 2025 | Jardiance |
| Axsome Therapeutics, INC. | $105.64 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $102.99 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $102.37 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $98.30 | 2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.21 | 2025 | Caplyta |
| Viatris Specialty LLC | $21.88 | 2025 | Yupelri |
| Verona Pharma, INC. | $20.81 | 2025 | Ohtuvayre |
| Astrazeneca Pharmaceuticals LP | $17.44 | 2025 | Breztri |
| Paratek Pharmaceuticals, INC. | $15.18 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Holbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.